Alex Michotte
Overview
Explore the profile of Alex Michotte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
639
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vanhauwaert D, Vanschoenbeek K, Weyns F, Vanopdenbosch L, Tieleman A, Michotte A, et al.
Cancer Med
. 2024 Oct;
13(21):e70045.
PMID: 39475180
Objectives: This study aimed to assess the diagnostic management and follow-up imaging for glioma patients across Belgian hospitals by calculating process indicators. Methods: Patients with newly diagnosed glioma in Belgium...
2.
Kros J, Rushing E, Uwimana A, Hernandez-Lain A, Michotte A, Al-Hussaini M, et al.
Neuro Oncol
. 2022 Dec;
25(8):1443-1449.
PMID: 36571817
Background: Gliomas with IDH1/2 mutations without 1p19q codeletion have been identified as the distinct diagnostic entity of IDH mutant astrocytoma (IDHmut astrocytoma). Homozygous deletion of Cyclin-dependent kinase 4 inhibitor A/B...
3.
Duerinck J, Schwarze J, Awada G, Tijtgat J, Vaeyens F, Bertels C, et al.
J Immunother Cancer
. 2021 Jun;
9(6).
PMID: 34168003
Background: Patients with recurrent glioblastoma (rGB) have a poor prognosis with a median overall survival (OS) of 30-39 weeks in prospective clinical trials. Intravenous administration of programmed cell death protein...
4.
Brock S, Michotte A, Done E, Leus A, Cannie M, De Pierre K, et al.
J Neuropathol Exp Neurol
. 2021 Apr;
80(8):807-810.
PMID: 33846711
No abstract available.
5.
Awada G, Ben Salama L, De Cremer J, Schwarze J, Fischbuch L, Seynaeve L, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33067319
Background: No treatment demonstrated to improve survival in patients with recurrent glioblastoma (rGB) in a randomized trial. Combining axitinib with the programmed cell death ligand 1 blocking monoclonal antibody avelumab...
6.
Jacqmot O, Van Thielen B, Michotte A, De Mey J, Provyn S, Tresignie J
Front Neuroanat
. 2020 Sep;
14:54.
PMID: 32973464
The first anatomical atlas of diffusion tensor imaging (DTI) of white matter pathways in the canine brain was published in 2013; however, the anatomical orientation of the entire visual pathway...
7.
Van Laethem D, Michotte A, Cools W, Velkeniers B, Unuane D, Andreescu C, et al.
Horm Metab Res
. 2020 Aug;
52(9):647-653.
PMID: 32757187
The aim of this study is to assess differences in patient characteristics, tumour characteristics and hormone levels between acromegalic patients with and without hyperprolactinemia. 44 patients of the University Hospital...
8.
Wiels W, Geens W, Vanderhasselt T, Michotte A, Van Velthoven V
Acta Neurol Belg
. 2019 Nov;
120(3):751-753.
PMID: 31745847
No abstract available.
9.
Du Four S, Janssen Y, Michotte A, van Binst A, Van den Begin R, Duerinck J, et al.
Cancer Med
. 2018 Aug;
7(10):4870-4879.
PMID: 30133176
Introduction: Up to 60% of patients with metastatic melanoma develop melanoma brain metastasis (MBM) during the course of their disease. Surgery, radiosurgery (SRS), stereotactic radiotherapy (SRT), and whole-brain radiation therapy...
10.
Lelotte J, Mourin A, Fomekong E, Michotte A, Raftopoulos C, Maiter D
Eur J Endocrinol
. 2017 Dec;
178(3):237-246.
PMID: 29259039
Introduction: Additional robust criteria to predict early postoperative recurrence of non-functioning pituitary macroadenomas (NFMAs) are needed. Recently, a new classification of pituitary tumors has been proposed, which is based on...